Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzupacap Sarotalocan (AU-011) in Metastases to the Choroid
NCT06643884Phase 2Recruiting
- Sponsor
- Aura Biosciences, Inc.
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Nanoparticles, Recombinant Proteins and Enzymes, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of belzupacap sarotalocan in choroidal metastasis, sponsored by Aura Biosciences, Inc.. Started Dec 2024; status: recruiting.
02
Drugs
belzupacap sarotalocan
03
Conditions
choroidal metastasis
Beyond the preview
Go deeper on NCT06643884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643884.